Lung Cancer
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305) (20200041)
- Details
ClinicalTrials.gov ID:
NCT06211036
Diagnosis Type:
NA
USOR Number:
- Address
,
P: